[{"patient_id":"SAMPLE1","drug":"warfarin","timestamp":"2026-02-19T23:52:49.944381+00:00","risk_assessment":{"risk_label":"Unknown","confidence_score":0.0,"severity":"low/moderate"},"pharmacogenomic_profile":{"primary_gene":"CYP2C9","diplotype":"Unknown","phenotype":"Unknown","detected_variants":[]},"clinical_recommendation":{"guideline_name":null,"drug_recommendation":null,"classification":null,"implications":null,"cpic_update":"The CPIC guideline lookup for warfarin has encountered an issue with no available URL.\n\nWarfarin is an anticoagulant that interacts with the CYP2C9 gene, which affects its metabolism. Variants in CYP2C9 can influence warfarin dose requirements. \n* Consider alternative dosing algorithms or consult a pharmacogenomics expert to estimate the appropriate warfarin dose.\n* If possible, genotype the patient for CYP2C9 to determine their phenotype and guide dosing decisions.\n* Monitor the patient's international normalized ratio (INR) closely to adjust the warfarin dose and minimize the risk of bleeding or thrombosis.","source":"llm_fallback_no_url"},"llm_generated_explanation":{"summary":"The CPIC guideline lookup for warfarin has encountered an issue with no available URL.\n\nWarfarin is an anticoagulant that interacts with the CYP2C9 gene, which affects its metabolism. Variants in CYP2C9 can influence warfarin dose requirements. \n* Consider alternative dosing algorithms or consult a pharmacogenomics expert to estimate the appropriate warfarin dose.\n* If possible, genotype the patient for CYP2C9 to determine their phenotype and guide dosing decisions.\n* Monitor the patient's international normalized ratio (INR) closely to adjust the warfarin dose and minimize the risk of bleeding or thrombosis."},"quality_metrics":{"vcf_parsing_success":true}},{"patient_id":"SAMPLE1","drug":"clopidogrel","timestamp":"2026-02-19T23:52:49.944381+00:00","risk_assessment":{"risk_label":"Unknown","confidence_score":0.0,"severity":"low/moderate"},"pharmacogenomic_profile":{"primary_gene":"CYP2C19","diplotype":"Unknown","phenotype":"Unknown","detected_variants":[]},"clinical_recommendation":{"guideline_name":null,"drug_recommendation":null,"classification":null,"implications":null,"cpic_update":"The CPIC guideline lookup for clopidogrel has encountered an issue due to the unavailability of a guideline URL.\n\nClopidogrel is an antiplatelet medication that requires metabolic activation by the CYP2C19 enzyme. Variants in the CYP2C19 gene can affect the metabolism of clopidogrel, potentially leading to reduced efficacy and increased risk of adverse cardiovascular events. \n* Consider alternative antiplatelet medications that are less dependent on CYP2C19 metabolism.\n* If clopidogrel is still chosen, monitor patients closely for signs of reduced efficacy, such as inadequate platelet inhibition.\n* Genetic testing for CYP2C19 variants may be considered to inform treatment decisions, although the clinical utility of this approach is still uncertain.","source":"llm_fallback_no_url"},"llm_generated_explanation":{"summary":"The CPIC guideline lookup for clopidogrel has encountered an issue due to the unavailability of a guideline URL.\n\nClopidogrel is an antiplatelet medication that requires metabolic activation by the CYP2C19 enzyme. Variants in the CYP2C19 gene can affect the metabolism of clopidogrel, potentially leading to reduced efficacy and increased risk of adverse cardiovascular events. \n* Consider alternative antiplatelet medications that are less dependent on CYP2C19 metabolism.\n* If clopidogrel is still chosen, monitor patients closely for signs of reduced efficacy, such as inadequate platelet inhibition.\n* Genetic testing for CYP2C19 variants may be considered to inform treatment decisions, although the clinical utility of this approach is still uncertain."},"quality_metrics":{"vcf_parsing_success":true}},{"patient_id":"SAMPLE1","drug":"simvastatin","timestamp":"2026-02-19T23:52:49.944381+00:00","risk_assessment":{"risk_label":"Unknown","confidence_score":0.0,"severity":"low/moderate"},"pharmacogenomic_profile":{"primary_gene":"SLCO1B1","diplotype":"Unknown","phenotype":"Unknown","detected_variants":[]},"clinical_recommendation":{"guideline_name":null,"drug_recommendation":null,"classification":null,"implications":null,"cpic_update":"The CPIC guideline lookup for simvastatin has encountered an issue due to the unavailability of a guideline URL.\n\nSimvastatin is a statin medication that interacts with the SLCO1B1 gene, which codes for a transporter involved in its hepatic uptake. Variants in this gene can affect simvastatin plasma levels and increase the risk of myopathy. \n* Consider alternative statins if SLCO1B1 genotype is available and indicates increased risk.\n* Monitor patients for signs of myopathy, such as muscle pain or weakness.\n* Adjust simvastatin dose or consider genotype testing if myopathy risk is a concern.","source":"llm_fallback_no_url"},"llm_generated_explanation":{"summary":"The CPIC guideline lookup for simvastatin has encountered an issue due to the unavailability of a guideline URL.\n\nSimvastatin is a statin medication that interacts with the SLCO1B1 gene, which codes for a transporter involved in its hepatic uptake. Variants in this gene can affect simvastatin plasma levels and increase the risk of myopathy. \n* Consider alternative statins if SLCO1B1 genotype is available and indicates increased risk.\n* Monitor patients for signs of myopathy, such as muscle pain or weakness.\n* Adjust simvastatin dose or consider genotype testing if myopathy risk is a concern."},"quality_metrics":{"vcf_parsing_success":true}}]